NEW YORK, June 21 (GenomeWeb News) - Paradigm Genetics has received a $742,000 phase I/II SBIR contract from the National Institute of Environmental Health Sciences for an effort to use metabolomics to discover biochemical pathways of drug-induced liver injury, the company said today.
The contract, "Metabolomics and Pathway Linkage: Urine, Serum, and Liver," includes $99,000 in funding for phase I, which is expected to run for six months, $643,000 for phase II, which is expected to run for two more years and will be awarded upon the completion of phase I. The contract is being awarded under the NIH Fast Track program, which is used to expedite awards for applications with high commercialization potential.
Under the contract, Paradigm will use mass spectrometry to conduct pre-clinical studies on three compounds known to cause liver damage, and will profile hundreds of small molecular weight biochemicals with a potential link to liver toxicity. The findings could lead to diagnostics and drug screening tools to provide earlier signals of liver injury, the company said.
" Paradigm's objective through this study is to identify non-invasive biomarkers that are more sensitive predictors of the early onset of liver injury," Thomas Colatsky, vice president of human health research at Paradigm Genetics, said in a statement. "These biomarkers may be useful as diagnostics that will help pharmaceutical companies to better assess drug candidate safety."